Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) A phase 2 trial

Journal of Immunotherapy

Volumn 31, Issue 6, 2008, Pages 577-585

  Amato, Robert J ^a   Drury, Noel ^b   Naylor, Stuart ^b   Jac, Jaroslaw ^a   Saxena, Somya ^a   Cao, Amy ^a   Hernandez McClain, Joan ^a   Harrop, Richard ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

5T4 tumor antigen; Cancer vaccine; Granulocyte macrophage colony stimulating factor; Hormone refractory prostate cancer; Modified vaccinia Ankara

Indexed keywords

CANCER ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; CANCER VACCINE; TROVAX;

ADD ON THERAPY; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BODY TEMPERATURE; BONE PAIN; CANCER GROWTH; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE IRRITATION; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SIDE EFFECT; TREATMENT RESPONSE; TUMOR VOLUME; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; MIDDLE AGED; PROSTATE TUMOR; VACCINATION; VACCINIA VIRUS;

AGED; AGED, 80 AND OVER; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; VACCINATION; VACCINIA VIRUS;

EID: 48549088424     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31817deafd     Document Type: Article

References (23)

1. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004;122:598-609.
2. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:239-246.
3. Myers KA, Rahi-Saund V, Davison MD, et al. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats. J Biol Chem. 1994;269:9319-9324.
4. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer. 2005;19:670-677.
5. Mulryan K, Ryan MG, Myers KA, et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther. 2002;1:1129-1137.
6. Harrop R, Ryan MG, Myers KA, et al. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother. 2006;55:1081-1090.
7. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;12:3416-3424.
8. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;13:4487-4494.
9. Jemal A, Siegel R, Ward E, et al. A cancer journal for clinicians. Cancer Stat. 2007;57:43-66.
10. Spitler LE, Grossbeard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony stimulating factor. J Clin Oncol. 2000;18:1614-1621.
11. Rini BWV, Bok R, Small EJ. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colonystimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003;21:99-105.
12. Small EJ, Reese DM, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5:1738-1744.
13. Small EHS, Picus J, Chen Y, et al. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Am Soc Clin Oncol. 2001;20. Abstract 695.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. Response evaluation criteria in solid tumors (RECIST). Committee J Natl Cancer Inst (Bethesda). 2000;92:205-216.
15. Kelly WK, Scher HI, Mazumdar M, et al. Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol. 1993;11:607-615.
16. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6:1632-1638.
17. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev. 2006;58:931-947.
18. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormonerefractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
19. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 2002;53:109-117.
20. Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia- PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999;53: 260-266.
21. Kantoff PW, Glode LM, Tannenbaum SI, et al. Randomised, double-blind, vector-controlled study of targeted immunotherapy in patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol. 2006;24:100s.
22. Ioannides CG, Whiteside TL. T-cell recognition of human tumors; implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol. 1993;66:91-106.
23. Gabrilovich D. Mechanisms and functional significance of tumourinduced dendritic-cell defects. Nat Rev Immunol. 2004;4:941-952.